Arpeggio Biosciences
Arpeggio Biosciences, Inc.
Arpeggio Biosciences, Inc. is a biotech innovator specializing in advanced drug discovery solutions through the integration of transcriptomics and artificial intelligence. By leveraging cutting-edge technology and vast datasets, the company is poised to revolutionize the identification of effective treatments for complex diseases.
Products & Team
GRETA™ Platform
The GRETA™ platform represents a cutting-edge technological frontier in drug discovery, merging proprietary biological assays with advanced machine learning algorithms. This synergy enables rapid, high-resolution analyses of cellular changes in response to drug treatments, pushing the boundaries of conventional drug development practices.
By addressing the challenge of drug discovery for complex diseases that cannot be attributed to a single protein target, GRETA™ empowers researchers to identify new drug targets and optimize treatment strategies based on intricate biological networks.
Arpeggio addresses significant pain points such as the identification of effective drug targets for complex diseases, the prediction of potential toxic side effects, and the mapping of drugs to diseases based on their broad biological impacts.